MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer

BACKGROUND: While PARP inhibitors and CDK4/6 inhibitors, the two classes of FDA-approved agents, have shown promising clinical benefits, there is an urgent need to develop new therapeutic strategies to improve clinical response. Meanwhile, extending the utility of these inhibitors beyond their respe...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Jingyan, Liu, Chongya, Tao, Zhiwei, Wang, Min, Jia, Yaxun, Sang, Xiaolin, Shen, Lanlin, Xue, Yijue, Jiang, Kui, Luo, Fuwen, Liu, Pixu, Cheng, Hailing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557734/
https://www.ncbi.nlm.nih.gov/pubmed/30898650
http://dx.doi.org/10.1016/j.ebiom.2019.03.027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557734/
https://www.ncbi.nlm.nih.gov/pubmed/30898650
http://dx.doi.org/10.1016/j.ebiom.2019.03.027

Ejemplares similares